Bristol-Myers to buy Celgene in a $74 billion deal; Celgene shares surge

Bristol-Myers on Thursday announced plans to buy Celgene in a deal the company valued at $74 billion.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.